Last reviewed · How we verify
Pneumovax 23TM — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Pneumovax 23TM (Pneumovax 23TM) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pneumovax 23TM TARGET | Pneumovax 23TM | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pneumovax 23TM CI watch — RSS
- Pneumovax 23TM CI watch — Atom
- Pneumovax 23TM CI watch — JSON
- Pneumovax 23TM alone — RSS
Cite this brief
Drug Landscape (2026). Pneumovax 23TM — Competitive Intelligence Brief. https://druglandscape.com/ci/pneumovax-23tm. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing